Ganirelix

What is Ganirelix?

Ganirelix (brand names ORGALUTRAN in Europe, originally ANTAGON in the US, currently marketed as FYREMADEL; development code RS-26306) is a synthetic decapeptide GnRH receptor antagonist approved by the FDA on July 29, 2000 for prevention of premature luteinizing hormone surges in women undergoing controlled ovarian stimulation in IVF.

It is structurally distinct from cetrorelix but functionally equivalent — both are dosed as 0.25 mg subcutaneous injections during the late follicular phase of an IVF cycle.

Structure and Mechanism

Ganirelix incorporates multiple D-amino acid and unnatural amino acid substitutions in the native GnRH backbone. Notable features include the homo-arginine (hArg) ethyl substitutions at positions 6 and 8, which provide high receptor affinity and enzymatic stability.

Like cetrorelix, ganirelix is a competitive antagonist at the GnRH receptor:

• Binds the receptor without activating it
• Produces immediate, reversible suppression of LH and FSH
• No initial gonadotropin flare
• Rapid pharmacokinetic onset and offset

In IVF, the practical consequence is the same as cetrorelix: prevention of the estradiol-driven premature LH surge that would otherwise trigger ovulation before egg retrieval.

Clinical Evidence

Ganirelix was studied alongside cetrorelix in the establishment of the modern GnRH antagonist IVF protocol. The Cochrane systematic review (Al-Inany et al., 2016) pooled antagonist trials (cetrorelix + ganirelix combined) vs the GnRH agonist long protocol:

• Equivalent live birth rates
• Lower OHSS risk (RR 0.61)
• Shorter cycle duration

Direct head-to-head trials of ganirelix vs cetrorelix have shown clinical equivalence; choice between them is based on formulary access and patient preference.

Approval History

• July 29, 2000 — FDA approval as Antagon (later renamed Fyremadel)
• 2000 — EMA approval as Orgalutran

Place in Therapy

Ganirelix is interchangeable with cetrorelix in standard antagonist IVF protocols. Dosing is 0.25 mg subcutaneous once daily during ovarian stimulation, typically starting on day 5-6 of FSH administration and continuing until the day of trigger injection (HCG or GnRH agonist).

Safety Profile

Adverse events are mild and largely reflect the IVF cycle context:

• Local injection-site reactions
• Mild hypersensitivity reactions (rare)
• Headache, nausea
• OHSS (lower risk than agonist protocols)

Because ganirelix is used briefly and clears rapidly, there are no chronic systemic safety concerns.

Distinction from Cetrorelix

Ganirelix and cetrorelix are functionally interchangeable in IVF protocols. Differences are minor:

Both have generic versions available, and clinical pregnancy outcomes are equivalent. Local availability and price are the typical drivers of selection.